Therefore, it is likely that TGFβR1 is not the rate limiting factor in this equation, and the observed increase in downstream pSMAD2/3 levels predominantly resulted from increased TGFβR2 levels via the excessive binding of activated TGF-β1 present in the animal PAH models and PAH patients. This evidence concerns the gene TGFBR1 and pulmonary arterial hypertension.